7Baggers

Celldex Therapeutics, Inc
(NASDAQ:CLDX) 

CLDX stock logo

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The...

Founded: 1983
Full Time Employees: 127
Sector: Healthcare
Industry: Biotechnology
Pharmaceuticals
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
    Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-09-30 2019-06-30 2019-03-31 2018-09-30 2018-06-30 2018-03-31 2017-09-30 2017-06-30 2017-03-31 2016-09-30 2016-06-30 2016-03-31 2015-09-30 2015-06-30 2015-03-31 2014-09-30 2014-06-30 2014-03-31 2013-09-30 2013-06-30 2013-03-31 2012-09-30 2012-06-30 2012-03-31 2011-09-30 2011-06-30 2011-03-31 2010-09-30 2010-06-30 2010-03-31 2009-09-30 2009-06-30 2009-03-31 2008-09-30 2008-06-30 2008-03-31 2007-09-30 2007-06-30 2007-03-31 2006-12-31 2006-09-30 2006-06-30 2006-03-31 2005-12-31 2005-09-30 2005-06-30 2005-03-31 2004-09-30 2004-06-30 2004-03-31 2003-09-30 2003-06-30 2003-03-31 2002-09-30 2002-03-31 2001-09-30 2001-06-30 
                                                                                      
      revenues:
    		                                                                                  
      product development and licensing agreements
    		50,000 40,000 3,000  2,000 8,000 2,000 16,000  259,000   30,000 26,000  26,000 3,000 2,000 12,000  3,000 4,000 12,000  2,286,000 55,000 195,000 129,000 131,000 1,667,000 992,000 1,238,000 694,000 556,000 493,000 604,000 453,000 377,000 334,000 342,000 284,000 200,000 35,000 40,000 47,000 30,000 28,000 40,000 35,000 40,000 11,000 14,000 1,371,000 1,399,000 1,347 1,339,000 1,497,000 1,501,847 1,245,442 870,504 119,864 100,508 10,018 8,086 182,371 35,475 17,446 2,619,974 52,302.25 78,692 59,060 71,457 144,300 124,400 2,124,400 1,232,900 217,700 169,400 4,493,900 585,300 663,800 731,600 
      contracts and grants
    		645,000 81,000 3,188,000 2,498,000 154,000 1,167,000 1,515,000 252,000 967,000 3,872,000 407,000 163,000 144,000 1,587,000 153,000 3,454,000 682,000 332,000 656,000 236,000 682,000 3,781,000 656,000 236,000 442,000 491,000 520,000 1,296,000 810,000 1,096,000 3,076,000 2,686,000 3,135,000 978,000 1,727,000 785,000 850,000 649,000 1,844,000 144,000 817,000 392,000 381,000 940,000 50,000 50,000 79,000 96,000 54,000 5,000     220 799,000  139,343 137,685 253,985                       
      total revenues
    		695,000 121,000 3,191,000 2,498,000 156,000 1,175,000 1,517,000 268,000 967,000 4,131,000 407,000 163,000 174,000 1,613,000 153,000 3,480,000 685,000 334,000 668,000 236,000 685,000 3,785,000 668,000 236,000 2,728,000 546,000 715,000 1,425,000 941,000 2,763,000 4,068,000 3,924,000                                                   
      yoy
    		345.51% -89.70% 110.35% 832.09% -83.87% -71.56% 272.73% 64.42% 455.75% 156.11% 166.01% -95.32% -74.60% 382.93% -77.10% 1374.58% 0.00% -91.18% 0.00% 0.00% -74.89% 593.22% -6.57% -83.44% 189.90% -80.24% -82.42% -63.69%                                                       
      qoq
    		474.38% -96.21% 27.74% 1501.28% -86.72% -22.54% 466.04% -72.29% -76.59% 914.99% 149.69% -6.32% -89.21% 954.25% -95.60% 408.03% 105.09% -50.00% 183.05% -65.55% -81.90% 466.62% 183.05% -91.35% 399.63% -23.64% -49.82% 51.43% -65.94% -32.08% 3.67%                                                    
      operating expenses:
    		                                                                                  
      research and development
    		52,614,000 75,333,000 45,263,000 39,687,000 31,661,000 46,939,000 34,535,000 26,252,000 26,798,000 30,426,000 21,572,000 20,731,000 17,056,000 22,899,000 13,557,000 12,356,000 12,720,000 14,678,000 10,708,000 9,705,000 12,720,000 10,425,000 10,708,000 9,705,000 11,695,000 11,101,000 10,081,000 11,151,000 11,918,000 21,448,000 21,875,000 21,915,000 24,999,000 25,793,000 25,009,000 25,711,000 27,447,000 24,656,000 26,490,000 25,125,000 26,185,000 24,100,000 27,070,000 20,417,000 15,090,000 14,090,000 11,769,000 11,114,000 10,769,000 8,594,000 7,169,000 6,853,000 7,215,000 7,256,000 6,438 7,241,000 7,802,000 8,685,941 6,626,059 7,611,666 4,486,774 4,457,475 4,967,629 4,958,702 4,837,466 4,416,320 4,463,899 4,348,707 -11,038,881 3,591,334 3,430,992 4,030,618 2,805,800 3,367,800 3,453,200 2,510,100 2,673,400 2,692,500 3,423,200 4,409,600 5,633,100 5,440,500 
      general and administrative
    		10,820,000 11,941,000 10,054,000 9,128,000 9,103,000 10,263,000 8,221,000 7,221,000 6,640,000 8,832,000 6,531,000 7,154,000 6,911,000 6,599,000 5,821,000 4,306,000 4,121,000 6,241,000 3,640,000 3,528,000 4,121,000 2,708,250 3,640,000 3,528,000 3,666,000 3,403,000 3,908,000 4,896,000 3,722,000 5,621,000 5,593,000 5,346,000 6,534,000 7,229,000 6,950,000 7,790,000 9,307,000 8,487,000 8,184,000 6,089,000 5,004,000 4,787,000 4,582,000 3,578,000 3,411,000 3,138,000 2,835,000 2,219,000 2,317,000 2,273,000 2,240,000 2,386,000 2,421,000 2,591,000 2,835 3,850,000 3,511,000 3,341,253 4,206,081 4,605,482 3,032,758 2,000,271 1,671,138 2,051,977 2,312,349 1,818,799 2,117,192 1,988,514 1,310,546.25 1,670,306 1,861,095 1,710,784 1,290,600 1,269,700 1,292,100        
      total operating expenses
    		63,434,000 87,274,000 55,317,000 48,815,000 40,764,000 57,202,000 42,756,000 33,473,000 33,438,000 51,758,000 28,103,000 36,559,000 23,431,000 29,498,000 20,977,000 16,920,000 17,324,000 20,674,000 15,010,000 11,601,000 17,324,000 28,566,000 15,010,000 11,601,000 15,595,000 12,390,000 12,972,000 19,366,000 8,705,000 19,636,000 123,745,000 35,885,000                                                   
      operating income
    		-62,739,000 -87,153,000 -52,126,000 -46,317,000 -40,608,000 -56,027,000 -41,239,000 -33,205,000 -32,471,000 -47,627,000 -27,696,000 -36,396,000 -23,257,000 -27,885,000 -20,824,000 -13,440,000 -16,639,000 -20,340,000 -14,342,000 -11,365,000 -16,639,000 -24,781,000 -14,342,000  -12,867,000                                                          
      yoy
    		54.50% 55.56% 26.40% 39.49% 25.06% 17.64% 48.90% -8.77% 39.62% 70.80% 33.00% 170.80% 39.77% 37.09% 45.20% 18.26% 0.00% -17.92% 0.00%  29.32%                                                              
      qoq
    		-28.01% 67.20% 12.54% 14.06% -27.52% 35.86% 24.20% 2.26% -31.82% 71.96% -23.90% 56.49% -16.60% 33.91% 54.94% -19.23% -18.20% 41.82% 26.19% -31.70% -32.86% 72.79%                                                             
      operating margin %
    		-9027.19% -72027.27% -1633.53% -1854.16% -26030.77% -4768.26% -2718.46% -12389.93% -3357.91% -1152.92% -6804.91% -22328.83% -13366.09% -1728.77% -13610.46% -386.21% -2429.05% -6089.82% -2147.01% -4815.68% -2429.05% -654.72% -2147.01% 0% -471.66% 0% 0% 0% 0% 0% 0% 0% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% 
      investment and other income
    		8,943,000 5,836,000 10,005,000 10,475,000 7,800,000 8,935,000 2,979,000 2,703,000 3,110,000 4,321,000 912,000 392,000 207,000 1,398,000 145,000 67,000 101,000 192,000 118,000 106,000 101,000 1,942,000 118,000 106,000 242,000 431,000 478,000 702,000 521,000 466,000 780,000 398,000 362,000 851,000 395,000 414,000 1,031,000 391,000 391,000 807,000 2,260,000 275,000 1,586,000 142,000 161,000 379,000 105,000 126,000 205,000 144,000 79,000 84,000 124,000 95,000 3,162  18,000 82,487 921,820 99,191 46,254 132,778 364,173 442,251 554,384 624,331 654,091 280,521 -469,788 149,662 169,764 151,129 120,400          
      net income
    		-53,796,000 -81,317,000 -42,121,000 -35,842,000 -32,808,000 -47,092,000 -38,260,000 -30,502,000 -29,361,000 -43,306,000 -26,784,000 -36,004,000 -23,050,000 -26,487,000 -20,452,000 -13,373,000 -16,538,000 -20,148,000 -14,224,000 -11,031,000 -16,538,000 -21,900,000 -14,224,000  -12,625,000 -11,413,000 -11,779,000 -17,239,000 -7,243,000 -16,407,000 -118,132,000 -26,363,000 -28,566,000 -34,261,000 -29,598,000 -31,952,000 -34,673,000 -31,980,000 -32,359,000 -30,174,000 -28,082,000 -28,274,000 -29,903,000 -23,140,000 -19,016,000 -17,332,000 -15,027,000 -13,773,000 -13,516,000 -11,772,000 -10,236,000 -10,059,000 -9,087,000 -9,525,000 -6,582 -7,174,000 -8,705,000 -7,703,877 -7,656,158 -10,260,510 -22,130,682  -5,505,246 -5,626,279 -6,212,075 -5,520,567 -5,670,299 -2,970,991 14,098,775 -4,514,434 -4,733,940 -4,868,499 -3,697,200 -3,898,800 -1,909,400 -2,115,700 -3,183,300 -3,362,200 -276,200 -4,913,600 -6,224,000 -5,660,300 
      yoy
    		63.97% 72.68% 10.09% 17.51% 11.74% 8.74% 42.85% -15.28% 27.38% 63.50% 30.96% 169.23% 39.38% 31.46% 43.79% 21.23% 0.00% -8.00% 0.00%  30.99% 91.89% 20.76%  74.31% -30.44% -90.03% -34.61% -74.64% -52.11% 299.12% -17.49% -17.61% 7.13% -8.53% 5.89% 23.47% 13.11% 8.21% 30.40% 47.68% 63.13% 99.00% 68.01% 40.69% 47.23% 46.81% 36.92% 48.74% 23.59% 155415.04% 40.21% 4.39% 23.64% -99.91% -30.08% -60.67%  39.07% 82.37% 256.25%  -2.91% 89.37% -144.06% 22.29% 19.78% -38.98% -481.34% 15.79% 147.93% 130.11% 16.14% 15.96% 591.31% -56.94% -48.85% -40.60%     
      qoq
    		-33.84% 93.06% 17.52% 9.25% -30.33% 23.08% 25.43% 3.89% -32.20% 61.69% -25.61% 56.20% -12.98% 29.51% 52.94% -19.14% -17.92% 41.65% 28.95% -33.30% -24.48% 53.97%   10.62% -3.11% -31.67% 138.01% -55.85% -86.11% 348.10% -7.71% -16.62% 15.75% -7.37% -7.85% 8.42% -1.17% 7.24% 7.45% -0.68% -5.45% 29.23% 21.69% 9.72% 15.34% 9.10% 1.90% 14.81% 15.01% 1.76% 10.70% -4.60% 144612.85% -99.91% -17.59% 13.00% 0.62% -25.38% -53.64%   -2.15% -9.43% 12.53% -2.64% 90.86% -121.07% -412.30% -4.64% -2.76% 31.68% -5.17% 104.19% -9.75% -33.54% -5.32% 1117.31% -94.38% -21.05% 9.96%  
      net income margin %
    		-7740.43% -67204.13% -1319.99% -1434.83% -21030.77% -4007.83% -2522.08% -11381.34% -3036.30% -1048.32% -6580.84% -22088.34% -13247.13% -1642.10% -13367.32% -384.28% -2414.31% -6032.34% -2129.34% -4674.15% -2414.31% -578.60% -2129.34% 0% -462.79% -2090.29% -1647.41% -1209.75% -769.71% -593.81% -2903.93% -671.84% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% NaN% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% 
      basic and diluted net loss per common share
    		-810 -1,230 -640 -540 -560 -710 -810 -650 -620 -840 -570 -770 -490 -570 -450 -340 -420 -430 -360 -500 -420 -580 -360  -730 -750 -840 -1,400 -40 -110 -840 -200 -230 -280 -290 -320 -350 -320 -330  -310 -320 -330 -290 -240 -230 -250 -230 -270 -270 -270 -310 -280 -300 -0.21 -450   -0.49 -0.67 -2.19 -0.07 -0.07 -0.07 -0.08 -0.07 -0.08 -0.04 -0.048 -0.06 -0.06 -0.07 -0.05 -0.05 -0.03 -0.03 -0.05 -0.06 -0.01 -0.08 -0.11 -0.1 
      shares used in calculating basic and diluted net loss per share
    		66,383 23 66,294 66,019 58,871 658 47,261 47,253 47,214 1,206 46,916 46,759 46,739 82 45,453 39,616 39,614 1,288 39,278 22,082 39,614 6,575.75 39,278 22,082 17,406 15,282 13,952 12,297 163,679 147,428 140,548 129,640 125,202 122,648 100,672 98,817 98,689 98,568 98,482  89,404 89,361 89,270 81,015 80,899 74,027 59,467 58,733 50,145 44,136 37,463 32,047 31,922 31,815 31,695 15,879 15,834  15,708,244 15,227,475 10,127,435 75,188,022 75,184,048                    
      comprehensive loss:
    		                                                                                  
      other comprehensive income:
    		                                                                                  
      unrealized gain on marketable securities
    		254 -139 3,508 -464 -1,064 -1,974 63 -51 863 1,173 305 -529 -1,782 -501.5 -44 5  -654 14 -3  -2.75 14  -22  36 19  31  11 15 21  36 380   11  80 1 138   52  108                                  
      comprehensive loss
    		-53,542 -81,456 -38,613 -36,306 -33,872 -49,066 -38,197 -30,553 -28,498 -42,133 -26,479 -36,533 -24,832 -25,115 -20,496 -13,368 -16,540 -20,802 -14,210 -11,034 -16,540 -9,472.75 -14,210  -12,647 -11,416 -11,743 -17,220 -7,251 -16,376 -118,137 -26,352 -28,551 -34,240 -29,711 -31,916 -34,293 -31,856 -32,539 -30,148 -28,206 -28,196 -29,901 -23,002 -19,157 -17,388 -14,974 -13,813 -13,406          -7,649,724 -10,413,386 -22,241,512                      
      gain on fair value remeasurement of contingent consideration
    		           -6,326,000 -536,000  -1,901,000                                                                    
      litigation settlement related loss
    		           15,000,000                                                                       
      intangible asset impairment
    		              3,500,000     3,500,000  875,000  3,500,000       18,677,000                                                    
      net loss before income tax benefit
    		             -26,487,000 -20,679,000   -20,148,000 -14,224,000 -11,259,000  -22,839,000 -14,224,000        -118,897,000                                                    
      income tax benefit
    		              227,000     228,000  939,000  228,000       765,000 5,200,000                                                   
      loss on fair value remeasurement of contingent consideration
    		               258,000 483,000 -290,000 662,000 -5,132,000 483,000 -1,059,000 662,000  234,000   1,519,000     1,000,000 3,400,000                                                 
      unrealized loss on marketable securities
    		                -2    -2                                                              
      other asset impairment
    		                           1,800,000                                                       
      goodwill impairment
    		                              90,976,000                                                    
      amortization of acquired intangible assets
    		                              224,000 224,000 224,000 224,000 254,000 254,000 253,000 254,000 254,000 253,000 254,000 254,000 253,000 254,000 254,000 253,000 254,000 291,000 291,000 656,000 483,000 483,000 483,000 658,000 1,520 95,000 95,000 95,309 103,974 104,164 48,894 240,048 240,048 240,048 248,776 248,778 248,778 248,778 186,583.5 248,778 248,778 248,778 248,800 248,800  248,800 248,800 248,800 198,800 198,800 344,000 344,000 
      other comprehensive income
    		                                                                                  
      in-process research and development impairment
    		                               13,000,000                                                   
      revenue:
    		                                                                                  
      total revenue
    		                                3,829,000 1,534,000 2,220,000 1,389,000 1,303,000 1,026,000 2,178,000 486,000 1,101,000 592,000 416,000 980,000 97,000 2,414,000 3,113,000 2,009,000 2,433,000 2,363,000 1,952,000 2,516,000 2,408,000 2,951,000 3,713 4,030,000 2,685,000 3,731,647 2,358,136 1,961,611 147,398 1,191,535 1,009,396 1,182,197 380,132 338,999 505,479 3,706,487 -2,450,947 846,322 637,161 970,552 527,600 893,000 3,030,700 2,015,100 1,078,400 681,700 4,560,400 690,900 725,500 825,800 
      operating expense:
    		                                                                                  
      total operating expense
    		                                32,757,000 36,646,000 32,213,000 33,755,000 37,007,000 33,397,000 34,928,000 31,467,000 31,443,000 29,141,000 31,905,000 24,249,000 18,755,000 19,815,000 17,864,000 15,497,000 15,721,000 13,841,000 11,833,000 12,174,000 11,287,000 12,237,000 13,120 11,186,000 11,408,000 11,518,011 10,936,114 12,321,312 22,324,334 6,697,794 6,878,815 7,250,727 7,398,591 6,483,897 6,829,869 6,585,999 -17,019,510 5,510,418 5,540,865 5,990,180 4,345,200 4,886,300 4,994,100 4,182,600 4,273,900 4,166,000 4,957,900 5,808,000 7,307,200 6,980,900 
      other comprehensive (loss) income:
    		                                                                                  
      foreign currency translation adjustments
    		                                       15   1    1  2                                  
      unrealized gain (loss) on marketable securities
    		                                     124                                             
      basic and diluted net income per common share
    		                                       -330                 -550 -0.49                         
      shares used in calculating basic and diluted net income per share
    		                                       92,437                  15,818,946                         
      product royalties
    		                                             2,334,000 3,006,000 1,873,000 2,344,000 2,318,000 1,941,000 2,502,000 1,037,000 1,552,000 2,146 1,892,000 1,188,000 2,090,457 975,009 837,122  1,000,878 910,379 911,852 30,476 23,105 27,510 586,306 22,036.5  55,138 33,008 49,100 53,900 26,400 48,500 42,100 35,300     
      royalty
    		                                             2,334,000 3,006,000 1,873,000 2,344,000 2,318,000 1,941,000 2,502,000 1,218,000 1,732,000 2,327                            
      interest expense
    		                                                                                  
      gain on sale of assets
    		                                                                                  
      charge for in-process research and development
    		                                                            14,755,908                      
      unrealized gain on foreign exchange translation
    		                                                          6,434                        
      unrealized gain on investment in select vaccines ltd.
    		                                                                                  
      government contracts and grants
    		                                                            27,534 90,149 88,999 262,259 167,285 280,419 460,523 500,207 -2,153,960 767,630 522,963 866,087 334,200 714,700         
      unrealized losses on foreign exchange translation
    		                                                                                  
      unrealized losses on investment in select vaccines ltd.
    		                                                                                  
      income before provision for income taxes
    		                                                             -5,373,481                     
      benefit from income taxes
    		                                                                                  
      provision for income taxes
    		                                                                -252,000   372,000               
      shares used in calculating basic and diluted earnings per share
    		                                                               75,183,981                   
      weighted-average common shares outstanding
    		                                                                 74,182,347 74,174,761 74,172,563 74,143 74,145,814 74,132,829 74,131,999 74,118,300 74,091,600 69,169,600 64,703,000   60,464,900 60,457,400 57,379,700  
      investment income
    		                                                                         94,500 54,000 51,800 12,200 122,100 121,300 203,500 357,700 494,800 
      government contracts
    		                                                                          879,900        
      amortization of intangible assets
    		                                                                          248,800        
      government contract revenue
    		                                                                           733,700 818,600 477,000     
      product sales
    		                                                                              66,500 105,600 61,700 94,200 
      selling, general and administrative
    		                                                                           1,423,700 1,351,700 1,224,700 1,325,600 1,185,900 1,321,700 1,188,200 
      cost of product sales
    		                                                                              10,300 13,700 8,400 8,200 
      weighted average common shares outstanding
    		                                                                            60,468,700 60,468,600    57,355,400 
      amortization of goodwill
    		                                                                                  
    Balance Sheets:
    Quarterly
    Annual
      Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-09-30 2019-06-30 2019-03-31 2018-09-30 2018-06-30 2018-03-31 2017-09-30 2017-06-30 2017-03-31 2016-09-30 2016-06-30 2016-03-31 2015-09-30 2015-06-30 2015-03-31 2014-09-30 2014-06-30 2014-03-31 2013-09-30 2013-06-30 2013-03-31 2012-09-30 2012-06-30 2012-03-31 2011-09-30 2011-06-30 2011-03-31 2010-09-30 2010-06-30 2010-03-31 2009-09-30 2009-06-30 2009-03-31 2008-09-30 2008-06-30 2008-03-31 2007-09-30 2007-06-30 2007-03-31 2006-12-31 2006-09-30 2006-06-30 2006-03-31 2005-12-31 2005-09-30 2005-06-30 2005-03-31 2004-09-30 2004-06-30 2004-03-31 2003-09-30 2003-06-30 2003-03-31 2002-09-30 2002-03-31 2001-09-30 2001-06-30 
                                                                                        
        assets
      		                                                                                  
        current assets:
      		                                                                                  
        cash and cash equivalents
      		35,729,000 28,871,000 36,037,000 23,044,000 17,136,000 28,356,000 36,399,000 42,739,000 115,077,000 34,814,000 21,134,000 28,224,000 54,123,000 29,429,000 18,583,000 28,401,000 25,293,000 39,143,000 72,184,000 43,446,000 69,313,000 43,836,000 18,151,000 68,027,000 22,724,000 16,586,000 19,744,000 31,533,000 32,823,000 43,894,000 39,824,000 54,735,000 66,162,000 42,497,000 31,743,000 32,482,000 63,025,000 66,791,000 81,584,000 122,170,000 32,525,000 40,797,000 56,902,000 14,626,000 25,900,000 75,627,000 23,187,000 18,563,000 22,755,000 13,097,000 10,830,000 10,140,000 9,828,000 15,158,000 42,666,000 25,985,000 31,633,000 39,364,362 42,697,228 52,379,836 11,418,544 20,339,659 25,909,541 32,573,796 40,911,539 46,681,330 53,468,716 59,755,919 23,419,434 22,198,775 27,028,598 27,309,120 35,228,300 39,370,700 41,161,500 23,498,400 16,984,100 19,750,400 26,314,000 37,054,200 34,736,900 40,706,000 
        marketable securities
      		415,729,000 489,702,000 547,186,000 607,293,000 656,155,000 696,925,000 719,600,000 759,578,000 708,769,000 388,784,000 214,214,000 224,473,000 224,264,000 275,523,000 304,888,000 328,416,000 355,175,000 369,107,000 350,905,000 120,591,000 106,770,000 150,586,000 181,443,000 138,888,000 30,998,000 56,332,000 61,598,000 53,535,000 72,795,000 70,115,000 83,424,000 85,795,000 87,822,000 124,526,000 171,505,000 187,646,000 190,992,000 237,819,000 252,408,000 237,603,000 191,553,000 211,572,000 217,324,000 121,962,000 129,083,000 106,750,000 54,428,000 60,109,000 69,374,000 49,677,000 60,406,000 34,167,000 47,829,000 50,674,000 32,700,000                            
        accounts and other receivables
      		230,000 2,015,000 90,000 90,000 1,064,000 700,000 852,000 1,534,000 2,671,000 2,628,000 252,000 118,000 1,314,000 347,000 189,000 97,000 243,000 172,000 197,000 496,000 1,828,000 1,802,000 838,000 329,000 1,108,000 727,000 1,170,000 2,307,000 3,175,000 3,423,000 4,020,000 3,013,000 1,359,000 1,384,000 1,579,000 1,116,000 847,000 527,000 434,000 679,000 2,905,000 525,000 305,000 890,000 12,000 104,000 32,000 61,000 140,000 204,000 163,000 243,000 456,000 738,000 859,000 1,091,000 1,013,000 1,077,107 11,481,828 1,538,044 176,072 525,600                     
        prepaid and other current assets
      		7,534,000 14,076,000 21,026,000 17,977,000 19,402,000 21,178,000 21,991,000 8,124,000 8,807,000 5,467,000 10,333,000 12,005,000 9,896,000 12,394,000 10,939,000 11,065,000 9,988,000 2,417,000 3,269,000 3,073,000 3,588,000 1,619,000 2,493,000 1,748,000 1,088,000 1,458,000 1,853,000 1,476,000 2,176,000 2,848,000 3,704,000 3,774,000 4,709,000 5,056,000 4,887,000 7,538,000 6,091,000 4,119,000 5,115,000 3,677,000 2,842,000 2,703,000 2,288,000 2,468,000 1,435,000 1,972,000 1,163,000 1,665,000 1,967,000 1,404,000 1,890,000 1,678,000 1,087,000 1,681,000 2,058,000 934,000 863,000 1,397,361       1,171,014    767,082              
        total current assets
      		459,222,000 534,664,000 604,339,000 648,404,000 693,757,000 747,159,000 778,842,000 811,975,000 835,324,000 431,693,000 245,933,000 264,820,000 289,597,000 317,693,000 334,599,000 367,979,000 390,699,000 410,839,000 426,555,000 167,606,000 181,499,000 197,843,000 202,925,000 208,992,000 55,918,000 75,103,000 84,365,000 88,851,000 110,969,000 120,280,000 130,972,000 147,317,000 160,052,000 173,463,000 209,714,000 228,782,000 260,955,000 309,256,000 339,541,000 364,129,000 229,825,000 255,597,000 276,819,000 139,946,000 156,430,000 184,453,000 78,810,000 80,398,000 94,236,000 64,382,000 73,289,000 46,228,000 59,200,000 68,251,000 78,283,000 28,010,000 33,509,000 41,838,830 55,560,730 69,025,814 22,676,922 21,380,377 27,329,094 33,924,551 42,403,494 48,162,887 54,992,315 61,249,898 24,604,896 28,592,909 33,088,810 28,894,316 36,614,800 40,201,100 43,443,800 24,781,800 18,035,000 20,971,400 29,144,600 37,762,300 35,912,200 42,411,600 
        property and equipment
      		7,396,000 5,334,000 4,829,000 4,392,000 4,601,000 4,346,000 4,230,000 3,864,000 4,061,000 4,060,000 4,162,000 3,938,000 3,995,000 3,747,000 3,753,000 3,744,000 3,484,000 3,551,000 3,342,000 3,496,000 3,747,000 3,815,000 3,813,000 4,044,000 4,116,000 4,488,000 5,086,000 5,462,000 6,699,000 7,478,000 9,785,000 11,308,000 12,069,000 12,411,000 11,355,000 11,293,000 11,392,000 11,864,000 11,735,000 11,236,000 10,716,000 10,601,000 10,216,000 8,814,000 7,338,000 7,131,000 7,566,000 7,998,000 8,447,000 9,539,000 9,985,000 10,472,000 10,924,000 10,972,000 10,965,000 12,015,000 12,551,000 13,015,741 14,190,971 14,033,088 14,592,563 17,072,700 16,555,004 15,551,013 13,967,800 10,534,372 7,950,494 6,203,757 5,743,663 5,119,239 4,788,560 4,430,436 2,171,700 1,113,200 1,053,100 972,900 1,068,700 1,114,000 1,038,200 1,029,000 1,084,000 977,100 
        operating lease right-of-use assets
      		2,012,000 2,437,000 2,717,000 3,121,000 3,514,000 3,898,000 3,170,000 2,450,000 2,165,000 2,577,000 2,864,000 3,256,000 3,633,000 4,001,000 3,580,000 3,944,000 2,564,000 2,970,000 3,016,000 2,718,000 3,088,000 3,449,000 3,801,000 3,134,000 3,739,000 3,431,000 3,974,000 4,445,000                                                       
        intangible assets
      		27,190,000 27,190,000 27,190,000 27,190,000 27,190,000 27,190,000 27,190,000 27,190,000 27,190,000 27,190,000 27,190,000 27,190,000 27,190,000 27,190,000 27,190,000 27,190,000 27,190,000 27,190,000 27,190,000 30,690,000 30,690,000 30,690,000 45,190,000 45,190,000 48,690,000 48,690,000 48,690,000 48,690,000 48,690,000 48,690,000 48,690,000 67,815,000 81,039,000 81,263,000 20,034,000 20,287,000 20,541,000 21,047,000 21,300,000 21,554,000 22,060,000 22,313,000 22,567,000 23,073,000 23,326,000 23,580,000 24,087,000 24,340,000 24,632,000 25,214,000 25,870,000 26,353,000 27,319,000 27,801,000 28,459,000 1,941,000 2,036,000 2,131,623 2,576,414 2,680,388 2,784,552                      
        other assets
      		15,434,000 13,358,000 9,364,000 9,300,000 10,409,000 9,747,000 9,747,000 107,000 107,000 107,000 107,000 107,000 104,000 104,000 104,000 104,000 104,000 104,000 98,000 41,000 41,000 41,000 41,000 41,000 41,000 129,000 129,000 129,000 1,929,000 1,929,000 1,929,000 2,002,000 1,935,000 1,935,000 1,879,000 1,879,000 78,000 1,500,000 1,676,000 1,816,000 99,000 116,000 132,000 157,000 174,000 236,000 409,000 428,000 460,000 348,000 367,000 386,000 5,401,000 5,582,000 5,773,000 6,136,000 6,316,000 6,496,643 6,857,420 262,767 262,099                      
        total assets
      		511,254,000 582,983,000 648,439,000 692,407,000 739,471,000 792,340,000 823,179,000 845,586,000 868,847,000 465,627,000 280,256,000 299,311,000 324,519,000 352,735,000 369,226,000 402,961,000 424,041,000 444,654,000 460,201,000 204,551,000 219,065,000 235,838,000 255,770,000 261,401,000 112,504,000 131,841,000 142,244,000 147,577,000 168,287,000 178,377,000 191,376,000 319,418,000 346,071,000 360,048,000 251,947,000 271,206,000 301,931,000 352,632,000 383,217,000 407,700,000 271,665,000 297,592,000 318,699,000 180,955,000 196,233,000 224,365,000 119,837,000 122,129,000 136,740,000 108,448,000 118,476,000 92,404,000 111,809,000 121,571,000 132,445,000 48,102,000 54,412,000 63,482,837 79,185,535 86,342,637 40,803,760 43,404,629 49,209,200 54,343,763 61,479,542 64,054,284 68,548,612 73,308,236 36,451,917 40,064,284 44,478,284 40,174,444 46,133,800 48,900,100 52,331,400 35,171,800 28,781,900 32,019,900 38,689,900 47,725,400 46,578,000 53,344,000 
        liabilities and stockholders’ equity
      		                                                                                  
        current liabilities:
      		                                                                                  
        accounts payable
      		10,359,000 1,180,000 4,267,000 2,073,000 3,410,000 3,265,000 1,114,000 3,802,000 3,234,000 3,494,000 3,586,000 881,000 3,374,000 3,340,000 2,272,000 902,000 1,019,000 1,228,000 836,000 685,000 997,000 1,048,000 568,000 950,000 1,609,000 666,000 1,016,000 1,105,000 2,311,000 2,942,000 508,000 1,278,000 1,975,000 2,660,000 1,019,000 706,000 2,637,000 1,217,000 2,020,000 3,071,000 1,720,000 1,187,000 3,414,000 1,982,000 2,069,000 2,451,000 1,281,000 395,000 535,000 457,000 514,000 738,000 741,000 1,073,000 1,617,000 1,153,000 1,375,000 1,497,573 1,405,789 1,329,434 1,880,035 1,022,861 887,593 1,017,921 2,552,089 831,138 661,277 598,510 1,140,578 476,868 617,205 1,136,158 650,400 307,900 427,300 259,100 187,100 349,000 496,800 258,400 872,700 613,100 
        accrued expenses
      		38,418,000 47,029,000 39,715,000 28,424,000 25,456,000 33,842,000 28,204,000 18,594,000 17,536,000 22,029,000 18,471,000 12,257,000 9,374,000 12,835,000 11,425,000 11,229,000 9,234,000 12,000,000 10,253,000 7,851,000 7,023,000 8,459,000 8,007,000 6,467,000 5,648,000 6,419,000 5,410,000 5,474,000 9,614,000 12,256,000 14,897,000 17,845,000 21,275,000 19,424,000 13,233,000 14,937,000 18,431,000 19,623,000 21,879,000 15,420,000 17,703,000 17,897,000 14,966,000 13,807,000 9,904,000 9,692,000 8,157,000 6,555,000 6,359,000 5,966,000 4,416,000 4,200,000 4,178,000 4,134,000 3,810,000 4,402,000 3,024,000 4,358,929 8,794,887 10,485,405 5,341,231 3,038,941 3,215,922 2,603,581 2,674,544 2,624,701 3,084,537 2,857,507 2,334,708 2,891,573 2,720,799 3,237,668 3,028,800 2,764,100 2,132,100 2,396,200 2,153,700 1,904,100 2,118,600 3,120,200 2,414,300 2,814,500 
        current portion of operating lease liabilities
      		1,465,000 1,552,000 1,553,000 1,536,000 1,499,000 1,452,000 1,379,000 1,589,000 1,644,000 1,614,000 1,547,000 1,530,000 1,493,000 1,445,000 1,438,000 1,425,000 1,802,000 1,746,000 1,366,000 1,331,000 1,372,000 1,327,000 1,263,000 1,320,000 1,682,000 2,253,000 2,538,000 2,633,000                                                       
        current portion of other long-term liabilities
      		1,230,000  930,000 930,000 1,653,000  1,396,000 3,673,000 3,877,000  4,232,000 978,000 978,000  1,152,000 1,393,000 2,505,000  1,721,000 4,621,000 7,585,000  2,362,000 2,104,000 1,993,000 2,550,000 2,545,000 2,777,000                                      222,542 231,022 210,157               
        total current liabilities
      		51,472,000 50,991,000 46,465,000 32,963,000 32,018,000 39,501,000 32,093,000 27,658,000 26,291,000 31,125,000 27,836,000 15,646,000 15,219,000 18,610,000 16,287,000 29,949,000 14,560,000 16,528,000 14,176,000 14,488,000 16,977,000 14,206,000 12,200,000 10,841,000 10,932,000 11,888,000 11,509,000 11,989,000 16,851,000 19,982,000 24,012,000 24,915,000 28,788,000 27,024,000 18,630,000 20,003,000 25,307,000 23,635,000 26,691,000 21,148,000 21,614,000 21,202,000 19,507,000 16,795,000 12,503,000 18,330,000 15,131,000 12,579,000 12,546,000 10,778,000 10,409,000 8,920,000 23,281,000 23,714,000 24,824,000 14,107,000 12,856,000 14,051,943 18,424,329 20,155,865 11,478,937 8,762,104 8,465,337 10,207,668 10,084,313 8,231,463 6,595,344 6,513,153 3,692,743 3,585,612 3,576,729 4,597,834 3,812,100 3,329,300 2,941,200 3,165,500 3,863,500 3,788,300 3,623,000 5,026,600 4,959,800 5,175,300 
        long-term portion of operating lease liabilities
      		443,000 784,000 1,068,000 1,495,000 1,929,000 2,361,000 1,708,000 796,000 470,000 928,000 1,299,000 1,725,000 2,157,000 2,588,000 2,190,000 2,586,000 841,000 1,296,000 1,713,000 1,446,000 1,764,000 2,154,000 2,545,000 1,720,000 2,106,000 1,482,000 1,867,000 2,599,000                                                       
        other long-term liabilities
      		3,113,000 4,043,000 2,543,000 2,543,000 2,543,000 3,473,000 3,473,000 3,473,000 3,473,000 4,403,000 4,403,000 4,403,000 4,403,000 5,333,000 5,333,000 5,333,000 10,539,000 7,354,000 7,600,000 6,335,000 6,158,000 10,121,000 11,050,000 10,396,000 15,763,000 17,091,000 19,242,000 20,296,000 23,302,000 30,348,000 33,282,000 75,351,000 85,826,000 85,188,000 16,225,000 16,494,000 16,592,000 10,370,000 10,648,000 11,000,000 10,679,000 11,075,000 7,346,000 7,415,000 6,636,000 6,668,000 6,365,000 6,394,000 6,418,000 5,981,000 5,994,000 6,002,000 5,587,000 5,798,000 6,024,000 989,000 1,026,000 1,054,323    4,702,491 4,815,954 4,516,433 4,165,126 3,089,611 2,323,785 2,004,333 1,870,051              
        total liabilities
      		55,028,000 55,818,000 50,076,000 37,001,000 36,490,000 45,335,000 37,274,000 31,927,000 30,234,000 36,456,000 33,538,000 21,774,000 21,779,000 26,531,000 23,810,000 37,868,000 25,940,000 25,178,000 23,489,000 22,269,000 24,899,000 26,481,000 25,795,000 22,957,000 28,801,000 30,461,000 32,618,000 34,884,000 40,153,000 50,330,000 57,294,000 100,266,000 114,614,000 112,212,000 34,855,000 36,497,000 41,899,000 34,005,000 37,339,000 32,148,000 32,293,000 32,277,000 26,853,000 24,210,000 19,139,000 29,424,000 28,822,000 27,581,000 28,854,000 27,774,000 26,471,000 26,619,000 59,788,000 61,569,000 63,986,000 50,342,000 50,109,000 51,692,636                         
        commitments and contingent liabilities
      		                                                                                  
        stockholders’ equity:
      		                                                                                  
        convertible preferred stock, .01 par value...
      		                                                                                  
        common stock, .001 par value...
      		67,000 67,000 66,000 66,000 66,000 66,000 66,000 66,000 66,000 56,000 47,000 47,000 47,000 47,000 47,000 47,000 47,000 47,000 47,000 40,000 40,000 40,000 40,000 39,000 18,000 16,000 15,000 13,000 169,000 157,000 143,000 132,000 127,000 124,000 101,000 99,000 99,000 99,000 99,000 98,000 89,000 89,000 89,000 81,000 81,000 81,000 61,000 59,000 59,000 44,000 44,000 32,000 32,000 32,000 32,000 16,000 16,000 15,821 15,708 15,708 14,927 74,408 74,404 74,404  74,403 74,397 74,393  74,381 74,353 74,353 74,300 74,300 74,300  60,500 60,500  60,500 57,400  
        additional paid-in capital
      		2,346,303,000 2,337,453,000 2,327,196,000 2,317,621,000 2,308,367,000 2,298,849,000 2,288,683,000 2,277,824,000 2,266,472,000 1,823,168,000 1,598,591,000 1,591,213,000 1,585,863,000 1,580,829,000 1,574,926,000 1,568,124,000 1,564,599,000 1,561,142,000 1,557,576,000 1,282,657,000 1,281,173,000 1,279,824,000 1,278,523,000 1,272,783,000 1,107,029,000 1,101,598,000 1,098,429,000 1,089,755,000 1,078,419,000 1,071,092,000 1,060,768,000 1,025,108,000 1,011,066,000 998,897,000 901,560,000 889,468,000 882,875,000 874,240,000 869,635,000 866,771,000 668,596,000 666,334,000 664,669,000 477,595,000 474,942,000 473,632,000 335,501,000 324,062,000 323,587,000 270,250,000 269,689,000 233,259,000 232,061,000 231,093,000 230,020,000 139,882,000 139,253,000 138,033,698 134,948,606 133,101,784 121,418,956 258,838,046 258,737,723 258,661,233 258,560,628 257,887,168 257,465,806 257,185,249 258,139,855 258,134,160 257,832,304 257,832,304 256,991,800 256,955,400 256,945,000 233,708,000 223,326,300 223,326,300 223,323,000 223,316,800 209,700,500 209,642,100 
        accumulated other comprehensive income
      		2,522,000 3,626,000 3,765,000 3,339,000 3,568,000 3,314,000 5,288,000 1,780,000 2,244,000 3,308,000 2,135,000 2,072,000 2,123,000 1,260,000 -112,000 -417,000 112,000 1,894,000 2,548,000 2,592,000 2,587,000 2,589,000 2,608,000 2,594,000 2,597,000 2,635,000 2,638,000 2,602,000 2,582,000 2,590,000 2,559,000 2,588,000 2,577,000 2,562,000 2,610,000 2,723,000 2,687,000 2,560,000 2,436,000 2,616,000 2,624,000 2,748,000 2,670,000 2,686,000 2,548,000 2,689,000 2,775,000 2,722,000 2,762,000 2,654,000 2,774,000 2,760,000 2,796,000 2,658,000 2,663,000 2,593,000 2,591,000 2,593,577 2,569,211 2,355,330 2,508,206                      
        accumulated deficit
      		-1,892,666,000 -1,813,981,000 -1,732,664,000 -1,665,620,000 -1,609,020,000 -1,555,224,000 -1,508,132,000 -1,466,011,000 -1,430,169,000 -1,397,361,000 -1,354,055,000 -1,315,795,000 -1,285,293,000 -1,255,932,000 -1,229,445,000 -1,202,661,000 -1,166,657,000 -1,143,607,000 -1,123,459,000 -1,103,007,000 -1,089,634,000 -1,073,096,000 -1,051,196,000 -1,036,972,000 -1,025,941,000                                                          
        total stockholders’ equity
      		456,226,000 527,165,000 598,363,000 655,406,000 702,981,000 747,005,000 785,905,000 813,659,000 838,613,000 429,171,000 246,718,000 277,537,000 302,740,000 326,204,000 345,416,000 365,093,000 398,101,000 419,476,000 436,712,000 182,282,000 194,166,000 209,357,000 229,975,000 238,444,000 83,703,000 101,380,000 109,626,000 112,693,000 128,134,000 128,047,000 134,082,000 219,152,000 231,457,000 247,836,000 217,092,000 234,709,000 260,032,000 318,627,000 345,878,000 375,552,000 239,372,000 265,315,000 291,846,000 156,745,000 177,094,000 194,941,000 91,015,000 94,548,000 107,886,000 80,674,000 92,005,000 65,785,000 52,021,000 60,002,000 68,459,000  4,303,000 11,790,201 23,837,728 29,433,183 28,162,960    2,160,980 7,699,595 12,798,794 18,188,534 20,889,123 24,688,120 29,049,669 33,662,609 41,979,000 45,570,800 49,390,200 31,923,400 24,711,000 27,899,800 34,912,900 40,390,300   
        total liabilities and stockholders’ equity
      		511,254,000 582,983,000 648,439,000 692,407,000 739,471,000 792,340,000 823,179,000 845,586,000 868,847,000 465,627,000 280,256,000 299,311,000 324,519,000 352,735,000 369,226,000 402,961,000 424,041,000 444,654,000 460,201,000 204,551,000 219,065,000 235,838,000 255,770,000 261,401,000 112,504,000 131,841,000 142,244,000 147,577,000 168,287,000 178,377,000 191,376,000 319,418,000 346,071,000 360,048,000 251,947,000 271,206,000 301,931,000 352,632,000 383,217,000 407,700,000 271,665,000 297,592,000 318,699,000 180,955,000 196,233,000 224,365,000 119,837,000 122,129,000 136,740,000 108,448,000 118,476,000 92,404,000 111,809,000 121,571,000 132,445,000 48,102,000 54,412,000 63,482,837 79,185,535 86,342,637 40,803,760 43,404,629 49,209,200 54,343,763 61,479,542 64,054,284 68,548,612 73,308,236 36,451,917 40,064,284 44,478,284 74,133,999 46,113,800 48,900,100 52,331,400 35,171,800 28,781,900 32,019,900 38,689,900 47,725,400   
        current portion of long-term liabilities
      		 1,230,000    942,000    3,988,000    990,000    1,554,000    3,372,000       4,926,000 4,784,000 8,607,000 5,792,000 5,538,000 4,940,000 4,378,000 4,360,000 4,239,000 2,795,000 2,792,000 2,657,000 2,191,000 2,118,000 1,127,000 1,006,000 530,000 557,000 399,000 335,000 358,000 264,000 479,000 649,000 1,076,000 1,174,000 2,387,000 229,000 221,000 213,464    577,630 575,714 546,479 477,606    217,457 204,674 213,727 186,509           
        litigation settlement payable
      		               15,000,000                                                                   
        goodwill
      		                               90,976,000 90,976,000 90,976,000 8,965,000 8,965,000 8,965,000 8,965,000 8,965,000 8,965,000 8,965,000 8,965,000 8,965,000 8,965,000 8,965,000 8,965,000 8,965,000 8,965,000 8,965,000 8,965,000 8,965,000 8,965,000 8,965,000 8,965,000 8,965,000       1,036,285 1,036,285 1,036,285 1,036,285 1,036,285 1,036,285 1,036,285 1,036,285 1,036,285 1,036,285 1,036,285 1,036,300 1,036,300 1,036,300 1,036,300 1,036,300 1,036,300 1,036,300 1,036,300   
        current portion of term loan
      		                                             5,630,000 5,294,000 5,294,000 5,294,000 4,091,000 5,000,000 3,333,000                               
        term loan, less current portion
      		                                             4,426,000 7,326,000 8,608,000 9,890,000 11,015,000 10,068,000 11,697,000                               
        convertible subordinated debt
      		                                                    12,230,000 12,048,000 11,866,000                            
        current portion of deferred revenue
      		                                                    5,056,000 5,285,000 5,144,000 5,366,000 5,279,000 5,024,729 5,043,160 5,132,279 1,093,324 4,122,672 3,786,108 6,039,687 4,380,074 4,553,082 2,618,508 2,846,981  12,497 24,998 37,499           
        deferred revenue
      		                                                    30,920,000 32,057,000 33,138,000 35,246,000 36,227,000 36,586,370 35,924,641 35,724,564 103,215 43,886,636 44,759,405 42,984,354 45,069,123 45,033,615 46,830,689 46,602,216 10,000,000 10,000,000 10,000,000  132,900          
        payable due medarex
      		                                                       2,957,000 2,957,000 2,957,248 2,957,248 2,987,528 2,945,050                      
        stockholders’ (deficit) equity:
      		                                                                                  
        total stockholders’ (deficit) equity
      		                                                                                  
        prepaid expenses and other current assets
      		                                                          1,381,674 15,107,934 11,082,306 515,118 1,317,116 1,112,149  927,199 787,928 777,760  750,714 583,141 668,745 770,700 290,300 629,700 714,900 465,100 536,500 706,300 421,200 863,000 1,057,300 
        current portion of deferred rent
      		                                                          57,447 57,447 57,447                      
        current portion of loans payable
      		                                                          165,798 163,772 161,850                      
        deferred rent
      		                                                          211,977 181,400 150,823                      
        loans payable
      		                                                          786,860 847,625 907,825                      
        stockholders’ equity
      		                                                                                  
        convertible preferred stock, 3,000,000 shares authorized; none issued and outstanding at september 30, 2008
      		                                                                                  
        convertible preferred stock, 1.00 par value; 1,000,000 shares authorized; none issued and outstanding at december 31, 2007
      		                                                                                  
        class a common stock, .01 par value...
      		                                                                                  
        common stock, .01 par value...
      		                                                                                  
        investment in select vaccines ltd
      		                                                           340,580 487,624 576,905                     
        convertible preferred stock, 3,000,000 shares authorized; none issued and outstanding at june 30, 2008
      		                                                                                  
        convertible preferred stock, 3,000,000 shares authorized; none issued and outstanding at march 31, 2008
      		                                                                                  
        intangible and other assets
      		                                                             3,338,362 3,591,866 3,831,914 4,071,963 4,320,740 4,569,518 4,818,296 5,067,073 5,315,851 5,564,629 5,813,407 6,311,000 6,549,500 6,798,200 8,380,800 8,641,900 8,948,200 7,470,800 7,897,800 9,581,800 9,955,300 
        convertible preferred stock, 4,513,102 shares authorized; none issued and outstanding
      		                                                                                  
        less: 220,319 common treasury shares at cost
      		                                                                                  
        accounts receivable
      		                                                              102,437 238,606 320,941 554,358 735,671 716,219 418,380 5,643,420 5,477,071 916,451 615,800 540,100 1,652,600 568,500 585,800 634,500 2,124,300 227,500 161,500 383,500 
        investment in select vaccines ltd.
      		                                                              696,951                    
        accumulated other comprehensive income: unrealized loss
      		                                                                                  
        convertible preferred stock, 4,513,102 shares authorized; none issued and outstanding at december 31, 2006 and 2005
      		                                                                                  
        common stock
      		                                                                74,403    74,387          60,500    
        deferred compensation
      		                                                                                  
        less: 220,319 common treasury shares at cost at december 31, 2006 and 2005
      		                                                                                  
        convertible preferred stock, 4,513,102 shares authorized; none issued and outstanding at december 31, 2005 and 2004
      		                                                                                  
        less: 220,319 common treasury shares at cost at december 31, 2005 and 2004
      		                                                                                  
        long-term liabilities
      		                                                                     1,790,552 1,851,886 1,914,001           
        note payable
      		                                                                        342,700          
        convertible preferred stock, 4,513,102 shares authorized; none issued and outstanding at september 30, 2004 and december 31, 2003
      		                                                                                  
        less: 220,300 common treasury shares at cost at september 30, 2004 and december 31, 2003
      		                                                                                  
        current portion deferred revenue
      		                                                                         257,300 381,800 510,200 1,522,700 1,535,200 1,007,600 1,648,000 1,623,000 1,622,900 
        convertible preferred stock, 4,513,102 shares authorized;none issued and outstanding at june 30, 2004 and december 31, 2003
      		                                                                                  
        less: 220,300 common treasury shares at cost at june 30, 2004 and december 31, 2003
      		                                                                                  
        convertible preferred stock, 4,513,102 shares authorized; none issued and outstanding at march 31, 2004 and december 31, 2003
      		                                                                                  
        less: 220,300 common treasury shares at cost at march 31, 2004 and december 31, 2003
      		                                                                                  
        long-term deferred revenue
      		                                                                           82,900 207,400 331,800 154,000 2,308,500 3,078,300 3,463,200 
        outstanding at september 30, 2003 and 60,464,900 issued and 60,332,300 outstanding at december 31, 2002
      		                                                                           64,900       
        less: 220,300 and 132,600 common treasury shares at cost at september 30, 2003 and december 31, 2002
      		                                                                                  
        less: 220,300 and 132,600 common treasury shares at cost at june 30, 2003 and december 31, 2002
      		                                                                                  
        less: 215,300 and 132,600 common treasury shares at cost at march 31, 2003 and december 31, 2002
      		                                                                                  
        inventories
      		                                                                               59,400 78,900 84,900 
        less: 40,700 common treasury shares at cost at september 30, 2002
      		                                                                                  
        current portion lease receivable
      		                                                                                71,900 179,900 
        liabilities and stockholders' equity
      		                                                                                  
        current portion lease payable
      		                                                                                49,800 124,800 
        stockholders' equity:
      		                                                                                  
        total stockholders' equity
      		                                                                                38,539,900 44,705,500 
        total liabilities and stockholders' equity
      		                                                                                46,578,000 53,344,000 
                                                                                        
      Cashflow Statements:
      Quarterly
      Annual
        Unit: USD2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-09-30 2019-06-30 2019-03-31 2018-09-30 2018-06-30 2018-03-31 2017-09-30 2017-06-30 2017-03-31 2016-09-30 2016-06-30 2016-03-31 2015-09-30 2015-06-30 2015-03-31 2014-09-30 2014-06-30 2014-03-31 2013-09-30 2013-06-30 2013-03-31 2012-09-30 2012-06-30 2012-03-31 2011-09-30 2011-06-30 2011-03-31 2010-09-30 2010-06-30 2010-03-31 2009-09-30 2009-06-30 2009-03-31 2008-09-30 2008-06-30 2008-03-31 2007-09-30 2007-06-30 2007-03-31 2006-12-31 2006-09-30 2006-06-30 2006-03-31 2005-12-31 2005-09-30 2005-06-30 2005-03-31 2004-09-30 2004-06-30 2004-03-31 2003-09-30 2003-06-30 2003-03-31 2002-09-30 2002-03-31 2001-09-30 2001-06-30 
                                                                                         
          cash flows from operating activities:
        		                                                                                 
          net loss
        		-81,317,000 -67,044,000 -56,600,000 -53,796,000 -47,092,000 -42,121,000 -35,842,000 -32,808,000 -43,306,000 -38,260,000 -30,502,000 -29,361,000 -26,487,000 -26,784,000 -36,004,000 -23,050,000 -20,148,000 -20,452,000 -13,373,000 -16,538,000 -21,900,000 -14,224,000 -11,031,000 -12,625,000 -11,413,000 -11,779,000 -17,239,000 -7,243,000 -16,406,000 -118,132,000 -26,363,000 -28,566,000 -34,261,000 -29,598,000 -31,952,000 -34,673,000 -31,980,000   -28,081,000 -28,274,000 -29,903,000 -23,140,000 -19,016,000 -17,332,000  -13,773,000 -13,516,000 -11,772,000 -10,236,000 -10,059,000 -9,087,000 -9,525,000 -6,582,000    -7,656,158 -10,260,510 -22,130,682 -5,253,481 -5,505,246 -5,626,279 -6,212,075 -5,520,567 -5,670,299 -2,970,991 -3,979,697 -4,514,433 -4,733,940 -4,868,499 -9,505,400 -5,808,200 -1,909,400 -8,661,200 -6,545,500 -3,362,200 -10,354,100 -4,913,600 -15,897,600 -9,673,600 
          adjustments to reconcile net loss to net cash from operating activities:
        		                                                                        836,100         
          depreciation and amortization
        		816,000 824,000 873,000 867,000 819,000 786,000 797,000 775,000 759,000 767,000 756,000 726,000 673,000 671,000 741,000 811,000 777,000 752,000 764,000 775,000 755,000 861,000 1,148,000 1,165,000 1,208,000 1,153,000 1,352,000 835,000 993,000 1,028,000 1,025,000 1,001,000 1,366,000 701,000 692,000 742,000 767,000 712,000 672,000 603,000 582,000 579,000 479,000 475,000 468,000 503,000 529,000 544,000 566,000 568,000 562,000 580,000 700,000 908,000 619,000 650,404 685,596 709,473 707,924 353,126 701,419 657,286 578,523 590,039 542,256 490,242 473,080 449,039 455,369 344,900 342,351 1,045,200  352,700 1,293,800 890,000 435,100 1,227,300 429,300 1,654,300 1,112,100 
          amortization and premium of marketable securities
        		-882,000 -1,018,000 -1,688,000 -2,267,000 -3,363,000 -4,333,000 -4,740,000 -3,313,000 -2,179,000 -1,627,000 -1,160,000 -1,256,000 -522,000 58,000 536,000 772,000 198,000 -3,234,000 -125,000 -48,000 -307,000 -87,000 -272,000 -63,000          156,000 83,000 529,000                                              
          loss on disposal of assets
        		                                                            1,866 0 74,148                   
          stock-based compensation expense
        		8,909,000 8,801,000 9,191,000 9,316,000 9,780,000 9,620,000 7,640,000 7,202,000 7,212,000 7,121,000 5,217,000 4,340,000 4,508,000 4,496,000 3,454,000 3,153,000 3,140,000 3,029,000 1,509,000 1,275,000 1,257,000 1,250,000 721,000 687,000 707,000 1,464,000 1,693,000 1,793,000 2,048,000 2,488,000 2,739,000 3,450,000 3,539,000 3,796,000 3,973,000 3,940,000 3,869,000 2,527,000 2,281,000 1,958,000 1,511,000 1,250,000 2,016,000 676,000 708,000 526,000 447,000 641,000 570,000 553,000 580,000 583,000 644,000 970,000 618,000 751,530 1,112,470 1,846,822 816,421 1,622,380 97,492 76,490 98,897  413,402 275,640 264,255               
          changes in operating assets and liabilities:
        		                                                                                 
          accounts and other receivables
        		-1,925,000 0 974,000 -364,000 152,000 682,000 1,137,000 -43,000 -2,376,000 -134,000 1,196,000 -967,000 -158,000 -92,000 146,000 -71,000 25,000 243,000 1,332,000 -26,000 -964,000 -509,000 779,000 -93,000 443,000 1,137,000 855,000     25,000 400,000   123,000      184,000    29,000 79,000 30,000 -41,000 80,000 81,000    -78,000 64,422 749,578                         
          prepaid and other current assets
        		8,471,000 -2,785,000 1,168,000 1,852,000 74,000 -14,351,000 599,000 -6,209,000 4,143,000 1,818,000 -2,783,000 2,722,000 -1,644,000 557,000 -1,337,000 -7,148,000 390,000 -717,000 593,000 -2,137,000 946,000 -844,000 -642,000 206,000   299,000 744,000                           -71,000        58,865          294,900   93,300 21,900     
          other assets
        		-3,994,000 -64,000 1,109,000 -662,000 0    0 0                     -67,000 0 199,000       17,000 16,000 16,000 17,000 62,000 188,000       181,000 191,000 182,000 180,000 180,336 180,664                         
          accounts payable and accrued expenses
        		4,601,000 13,062,000 2,086,000 -8,718,000 7,994,000 6,707,000 1,714,000 -4,781,000 3,877,000 8,477,000 478,000 -3,448,000 2,403,000 1,582,000 1,876,000 -2,738,000 1,896,000 2,507,000 516,000 -1,266,000 774,000 1,118,000 599,000 -853,000                   2,845,000 -97,000 206,000            111,950 -4,431,576 4,573,573 1,285,405            1,750,000 1,142,800 630,300        
          other liabilities
        		1,381,000 -410,000 -1,120,000 -604,000 -844,000 -2,691,000 -632,000 -1,469,000 -663,000 2,845,000 -395,000 -1,325,000 -536,000 -624,000 -387,000 4,273,000 -550,000 127,000 -3,404,000 -578,000 675,000 -79,000 -644,000 -768,000                -323,000 4,720,000 595,000 1,270,000 -354,000 516,000 47,000 -33,000 606,000                                  
          net cash from operating activities
        		-63,940,000 -48,628,000 -44,005,000 -54,372,000 -32,476,000 -55,337,000 -29,327,000 -40,638,000 -32,533,000 -18,993,000 -27,196,000 -28,569,000 -21,762,000 -35,192,000 -22,244,000 -24,534,000 -14,523,000 -16,372,000 -11,930,000 -18,084,000 -5,211,000 -11,861,000 -11,222,000 -12,110,000                                  -8,978,729       -3,863,325 -4,249,613 37,086,462               
          capital expenditures
        		-1,281,000 -440,000 -728,000 -265,000 -756,000 -545,000 -274,000 -344,000 -666,000 -157,000 -410,000 -585,000 -235,000 -345,000 -673,000 -575,000 -354,000 -185,000 -143,000 -567,000 -247,000 -160,000 -910,000 -235,000                                  0       0 0 0               
          free cash flows
        		-65,221,000 -49,068,000 -44,733,000 -54,637,000 -33,232,000 -55,882,000 -29,601,000 -40,982,000 -33,199,000 -19,150,000 -27,606,000 -29,154,000 -21,997,000 -35,537,000 -22,917,000 -25,109,000 -14,877,000 -16,557,000 -12,073,000 -18,651,000 -5,458,000 -12,021,000 -12,132,000 -12,345,000                                  -8,978,729       -3,863,325 -4,249,613 37,086,462               
          cash flows from investing activities:
        		                                                                                 
          sales and maturities of marketable securities
        		111,500,000 116,915,000 172,836,000 195,037,000 153,982,000 148,362,000 122,059,000 77,311,000 70,894,000 39,553,000 83,150,000 127,000,000 87,800,000 86,110,000 78,911,000 27,845,000 45,947,000 13,000,000 38,000,000 78,000,000 68,000,000 8,600,000 24,800,000 22,200,000 24,087,000 29,500,000 37,886,000 72,153,000 59,311,000 46,871,000 32,213,000 77,734,000 73,736,000 45,548,000 74,428,000 74,939,000 43,004,000 29,278,000 57,067,000 38,628,000 19,304,000 31,283,000 10,097,000 13,188,000 7,394,000 24,513,000 15,007,000 5,912,000 19,959,000 9,741,000 8,653,000 10,958,000 12,436,000 6,816,000                            
          purchases of marketable securities
        		-54,794,000 -55,628,000 -122,258,000 -151,822,000 -129,179,000 -100,059,000 -168,508,000 -392,178,000 -241,389,000 -27,750,000 -81,576,000 -73,846,000 -56,352,000 -62,766,000 -52,957,000 -16,890,000 -64,539,000 -239,603,000 -51,769,000 -33,970,000 -36,927,000 -50,955,000                                                            
          acquisition of property and equipment
        		-1,281,000 -440,000 -728,000 -265,000 -756,000 -545,000 -274,000 -344,000 -666,000 -157,000 -410,000 -585,000 -235,000 -345,000 -673,000 -575,000 -354,000 -185,000 -143,000 -567,000 -247,000 -160,000 -910,000 -235,000                                                          
          net cash from investing activities
        		55,425,000 60,847,000 49,850,000 42,950,000 24,047,000 47,758,000   -171,161,000 11,646,000 1,164,000 52,569,000 31,213,000 23,068,000 25,281,000 10,380,000 -18,944,000 -226,787,000 -13,912,000 43,487,000 30,852,000 -42,506,000 -108,529,000 21,965,000 5,519,000 -7,959,000 16,296,000 -2,221,000 13,194,000 15,495,000 1,665,000 35,784,000 22,401,000 14,918,000 667,000 25,539,000               5,270,000    -115,000 -184,643 709,643                         
          cash flows from financing activities:
        		                                                                                 
          net proceeds from stock issuances
        		    0 0 0 432,298,000         0    -172,000 4,297,000 165,054,000 1,613,000 2,463,000 7,212,000 4,151,000 5,493,000 8,271,000 11,689,000 11,153,000 8,668,000 12,821,000 8,115,000   0 66,000 188,774,000    0 0 114,187,000 10,915,000 28,000 51,929,000 -9,000   385,000 429,000 187,000 11,000 467,922 10,078                         
          proceeds from issuance of stock from employee benefit plans
        		1,349,000 774,000 63,000 202,000 386,000 1,239,000 3,712,000 3,814,000 1,152,000 257,000 133,000 694,000 1,395,000 2,306,000 71,000 304,000 426,000 2,004,000 -25,000 74,000 216,000 194,000 0 24,000 0 0 9,000 45,000 0 374,000 116,000 0 76,000 183,000 69,000 280,000 736,000 272,000 2,985,000 304,000 154,000 702,000 637,000 634,000 1,660,000                                     
          net cash from financing activities
        		1,349,000 774,000 63,000 202,000 386,000 1,239,000 3,712,000 436,112,000 217,374,000 257,000 133,000 694,000 1,395,000 2,306,000 71,000 304,000 426,000 271,897,000 -25,000 74,000 44,000 4,491,000 165,054,000 1,637,000 2,463,000 7,212,000 4,160,000 5,538,000 8,271,000 12,063,000 11,269,000 8,668,000 12,897,000 8,298,000     191,759,000 304,000 154,000 702,000 622,000 -9,086,000 114,509,000 9,580,000 -1,309,000 51,914,000 -23,000   334,000 381,000 141,000 -31,000   -89,019              23,357,700 23,321,300  9,194,200      447,100 
          net increase in cash and cash equivalents
        		-7,166,000 12,993,000 5,908,000 -11,220,000 -8,043,000 -6,340,000 -72,338,000 80,263,000    24,694,000 10,846,000   -13,850,000 -33,041,000 28,738,000 -25,867,000 25,477,000 25,685,000 -49,876,000 45,303,000 11,492,000   7,223,000    -11,427,000 23,665,000 36,000      94,150,000     -49,727,000 50,730,000 4,624,000 -4,192,000 10,856,000          -9,682,608              14,977,300          
          cash and cash equivalents at beginning of period
        		0 0 0 28,356,000 0 0 0 34,814,000 0 0 0 29,429,000 0 0 0 39,143,000 0 0 0 43,836,000 0 0 0 11,232,000 0 0 24,310,000 0 0 40,288,000 0 0 42,461,000 0 0 72,108,000 0 0 28,020,000 0 0 169,402,000 0 0 24,897,000 0 0 11,899,000 0 0 21,287,000 0 0 57,002,000 0 -286 44,257,286 0 0 4,909,530 0 0 40,911,539 0 0 0 23,419,434 0 0 0 31,741,494 20,251,000 20,251,000 20,251,000 25,070,700 25,070,700 25,070,700 42,665,900 42,665,900 50,177,000 50,177,000 
          cash and cash equivalents at end of period
        		-7,166,000 12,993,000 5,908,000 17,136,000 -8,043,000 -6,340,000 -72,338,000 115,077,000 13,680,000 -7,090,000 -25,899,000 54,123,000 10,846,000 -9,818,000 3,108,000 25,293,000 -33,041,000 28,738,000 -25,867,000 69,313,000 25,685,000 -49,876,000 45,303,000 22,724,000 -3,158,000 -11,789,000 31,533,000 -11,071,000 4,070,000 39,824,000 -11,427,000 23,665,000 42,497,000 -739,000 -30,543,000 63,025,000 -14,793,000 -40,586,000 122,170,000 -8,272,000 -16,105,000 56,902,000 -11,274,000 -49,727,000 75,627,000 4,624,000 -4,192,000 22,755,000 2,267,000 690,000 10,140,000 -5,330,000 -27,508,000 42,666,000 -5,648,000 -7,731,362 39,364,362 -9,682,608 40,961,292 11,418,544 -5,569,882 -6,664,255 32,573,796 -5,769,791 -6,787,386 -6,287,203 59,755,919 1,220,659 -4,829,823 -280,522 27,309,120 35,228,300 39,370,700 41,161,500 23,498,400 16,984,100 19,750,400 26,314,000 37,054,200 34,736,900 40,706,000 
          non-cash investing activities
        		                                                                                 
          accrued construction in progress
        		-374,000 423,000 -455,000 504,000 -205,000 215,000 -88,000 105,000 -411,000 442,000 -88,000 134,000 75,000 -16,000 1,000 53,000 243,000    158,000 41,000 -440,000 462,000  -10,000 65,000   212,000                                                    
          loss on sale or disposal of assets
        		 6,000 2,000 4,000 4,000 4,000 0 8,000     1,000 -56,000       -26,000 -9,000   0 -18,000 25,000 101,000 1,059,000 10,000    0 4,000 70,000                                              
          gain on fair value remeasurement of contingent consideration
        		            0    -245,000    18,000                                                             
          proceeds from sale or disposal of assets
        		            0    2,000 1,000 0 24,000 26,000 9,000                     0   62,000   4,000      0 -100 850,100                         
          net cash (used in ) provided by investing activities
        		       -315,211,000                                                                          
          intangible asset impairment
        		                0    14,500,000 0      0 0 18,677,000                                                    
          non-cash income tax benefit
        		                0    -939,000 0                                                            
          net decrease in cash and cash equivalents
        		         -7,090,000                                                                        
          litigation settlement payable
        		                                                                                 
          issuance of term loan
        		                    0 0                           0 0 5,000,000                               
          payment of term loan
        		                    0 0                                                            
          loss on fair value remeasurement of contingent consideration
        		              -6,326,000 -536,000   258,000 483,000   -5,132,000 234,000  -1,017,000 1,519,000     1,000,000 3,400,000                                                 
          gain on sale or disposal of assets
        		                 1,000 0 -24,000                                                              
          other asset impairment
        		                        0 0 1,800,000                                                       
          amortization of intangible assets
        		                           0 0 224,000 224,000 224,000 224,000 253,000 254,000 253,000 253,000 254,000 253,000 253,000 254,000 253,000 253,000 254,000 253,000 253,000 292,000 291,000 656,000 483,000 483,000 482,000 658,000 1,520,000 95,000 95,691 95,309 103,974 104,164 48,894                      
          goodwill impairment
        		                           0 0 90,976,000                                                    
          non-cash supplemental disclosure
        		                                                                                 
          shares issued to former kolltan executive for settlement of severance
        		                           8,000 19,000 38,000 39,000 54,000 209,000                                                 
          non-cash expense
        		                                 0 0 1,638,000 72,000 72,000 72,000                                           
          in-process research and development impairment
        		                                                                                 
          income tax benefit
        		                                                                                 
          investment in other
        		                                                                                 
          acquisition of property and equipment included in accounts payable and accrued expenses
        		                              -12,000 -283,000 370,000 -43,000 -170,000 278,000 -465,000 -336,000 839,000                                           
          effect of exchange rate changes on cash and cash equivalents
        		                                    0 0 15,000   1,000    1,000 -1,000 2,000    0                              
          net cash provided by financing activities
        		                                   280,000 736,000                       128,856                   35,100 505,500  
          realized gain on sales and maturities of marketable securities
        		                                                                                 
          net increase (decrease) in cash and cash equivalents
        		                                    -14,793,000                       6,509,014     -6,787,386 -6,287,203 36,336,485               
          net income
        		                                      -30,174,000                -7,174,000 -8,704,123 -7,703,877                         
          adjustments to reconcile net income to net cash from operating activities:
        		                                                                                 
          adjustments to reconcile net loss to net cash used in operating activities:
        		                                                                                 
          non-cash interest expense
        		                                          0 41,000 56,000 58,000 54,000 57,000 58,000 57,000 135,000 182,000 182,000 182,000                            
          payments of term loan
        		                                                                                 
          payments of other liabilities
        		                                                                                 
          loss on sales or disposal of assets
        		                                               23,000                                  
          proceeds from sales or disposal of assets
        		                                               11,000   64,000                               
          adjustments to reconcile net income to net cash used in operating activities:
        		                                                                                 
          realized (gain) loss on sales and maturities of marketable securities
        		                                                                                 
          (payments) issuance of term loan
        		                                                                                 
          payment of convertible subordinated debt
        		                                                                                 
          realized loss on sales and maturities of marketable securities
        		                                                -3,000 3,000 5,000                               
          deferred revenue
        		                                                       -105,059 191,059 110,958      -137,500 137,500 0 39,449,197 4,987,503 -12,501 4,987,499 25,795     776,200 913,100     
          payments of other long-term liabilities
        		                                                                                 
          other long-term liabilities
        		                                                 -166,000 288,000    13,000 19,405 30,595    -54,901 384,998 494,430 1,367,330 812,017 394,627 198,707               
          amortization of accretion of marketable securities
        		                                                  244,000                               
          gain on sales or disposal of assets
        		                                                                                 
          amortization and accretion of marketable securities
        		                                                                                 
          loss on sales and maturities of marketable securities
        		                                                   -9,000 10,000 21,000                            
          supplemental disclosure of non-cash flow information
        		                                                                                 
          shares issued to executive officers
        		                                                      0 0 250,000                         
          adjustments to reconcile net income to net cash (used in) provided by operating activities:
        		                                                                                 
          (gain) loss on sale or disposal of assets
        		                                                                                 
          in-process research and development
        		                                                         0 0 14,755,908                      
          cash acquired in avant merger, net of transaction costs
        		                                                                                 
          restricted cash deposits
        		                                                                                 
          related party loan due to medarex
        		                                                         -30,280 42,478 148,115                      
          shares received in exchange in the avant merger
        		                                                                                 
          shares issued to medarex in settlement of a payable
        		                                                         0 0 3,038,617                      
          future amounts payable to licensors
        		                                                                                 
          cash acquired in the acquisition of avant, net of transaction costs
        		                                                         0 0 10,750,255                      
          shares received in exchange in the acquisition of avant
        		                                                                                 
          shares received in exchange in the merger
        		                                                         0 0 46,251,952                      
          unpaid capitalized merger costs
        		                                                           150,441                      
          supplemental disclosure of cash flow information
        		                                                                                 
          cash paid for interest
        		                                                        52,398    54,092 -8,769 31,699 16,495 25,521 25,997 35,737 18,514 38,009 20,777 31,108           
          impairment of investment in select vaccines limited
        		                                                                                 
          loss on impairment & disposal of assets
        		                                                         4,345                        
          deferred rent
        		                                                         30,577 30,577 616                      
          proceeds from sale of shares of select vaccines limited
        		                                                                                 
          proceeds from disposal of assets
        		                                                         9,255                        
          cash from investing activities
        		                                                         -621,293                        
          net proceeds from stock issuance
        		                                                         0                        
          payments of loans payable
        		                                                                                 
          cash from (used in) investing activities
        		                                                           10,737,322                      
          impairment of investment in select vaccines ltd
        		                                                                                 
          other non-current assets
        		                                                                      1,000           
          investment in select vaccines limited
        		                                                                                 
          proceeds from stock issuance
        		                                                            2,835 0 1,709  7,752 0 6,145  3,383 0 2,055 23,051,000 23,051,000 23,090,700 9,274,600       
          proceeds from exercise of stock options and warrants
        		                                                               13,898 214   11,138 28,501 0 427 306,700 270,300 220,200 10,900 3,400 3,400 41,200 35,100 505,500 447,100 
          payments of long-term liabilities
        		                                                                                 
          accounts receivable
        		                                                             136,169 82,335     225,040 -166,349 439,380 1,313,899 1,199,700 932,700      39,700   
          cash flows from investing activity:
        		                                                                                 
          cash from investing activity
        		                                                                                 
          payment of long-term liabilities
        		                                                                                 
          adjustments to reconcile net loss to cash
        		                                                                                 
          provided by (used in) operating activities:
        		                                                                                 
          stock-based compensation
        		                                                                                 
          changes in assets and liabilities
        		                                                                                 
          net cash provided by (used in) operating activities
        		                                                                                 
          other non current assets
        		                                                                                 
          proceeds from the maturity of marketable securities
        		                                                                                 
          proceeds from (payment of) long-term liabilities
        		                                                                                 
          net cash provided by (used in) financing activities
        		                                                                                 
          increase (decrease) in cash and cash equivalents
        		                                                                                 
          income taxes paid
        		                                                                                 
          see note 9.
        		                                                                                 
          adjustments to reconcile net loss to cash from operating activities:
        		                                                                                 
          cumulative effect of change in accounting principle
        		                                                                                 
          amortization of deferred compensation
        		                                                                   175,000 121,000 121,000 121,000 207,000  69,000 46,000       
          changes in assets and liabilities, net of acquisition:
        		                                                                                 
          cash paid for acquisition of universal preservation technologies, inc. assets
        		                                                                                 
          net cash provided by (used in) investing activities
        		                                                                                 
          purchases of treasury stock
        		                                                                                 
          see note 6.
        		                                                                                 
          supplemental disclosure of noncash financing activities
        		                                                                                 
          note payable from massdevelopment
        		                                                                       342,700          
          see note 8.
        		                                                                                 
          increase in patents
        		                                                                                 
          changes in assets and liabilities:
        		                                                                                 
          increase in cash and cash equivalents
        		                                                                        19,119,700         
          net cash (used in) provided by financing activities
        		                                                                         23,310,900        
          decrease in cash and cash equivalents
        		                                                                         20,910,500        
          inventories
        		                                                                             71,500 12,100   
          increase in other assets
        		                                                                                 
          increase in patents and licenses
        		                                                                                 
          write-off of capitalized patent costs
        		                                                                               22,400 22,400 
          prepaid expenses and other current assets
        		                                                                               158,200  
          increase in other non-current assets
        		                                                                                 
          lease receivable
        		                                                                               323,800 215,800 
          lease payable
        		                                                                                 
          adjustments to reconcile net loss to net cash
        		                                                                                 
          used in operating activities:
        		                                                                                 
          decrease in restricted cash